Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therap
Kyverna Therapeutics has announced the pricing of its initial public offering, and in another sign of the improving biotech financing environment has raised its target pro
AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to
AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on
The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc
Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.